Sarcomas

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

The FDA has accepted an NDA for pimicotinib in tenosynovial giant cell tumor, supported by data from the phase 3 MANEUVER trial.

R. Lor Randall, MD, FACS, discusses global variation in DAIR strategies for post–limb salvage infections, highlighting needs for standardization and multidisciplinary coordination.

Richard Gorlick, MD, is a leading physician-scientist whose career and lifelong commitment to improving outcomes for children with cancer has been shaped by his personal journey as a childhood cancer survivor.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

The NMPA of China has approved pimicotinib, a CSF-1R inhibitor, for the treatment of adults with symptomatic TGCT.

R. Lor Randall, MD, FACS, discusses findings from a phase 2 study of denosumab in patients with osteosarcoma.

The first pediatric cancer progress report published by AACR identified strengths and weaknesses of contemporary pediatric cancer research.

Varegacestat improved progression-free survival vs placebo in patients with progressing desmoid tumors.

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.

Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.

R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Targeted gene therapy kills herpesvirus-linked cancer cells, sparing healthy tissue

Abemaciclib was safe and active for the treatment of patients with HIV-associated and -negative Kaposi sarcoma.

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in September 2025.